drugset / Trial / NCT02527421
DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
Timeline
- Start
- 2015-08-19
- Primary completion
- 2019-03-30
- Completion
- 2019-03-30
Outcome
Outcome not reported
Stopped (Enrollment): “Not able to recruit patients with the current enrollment criteria.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | betamethasone dipropionate | Small molecule | 0.05 % | Topical |